Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Enhertu | Vintage Vibes

First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled

Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.

Medical Daily · Sep 17

NHS Approves Breast Cancer Drug Rejected Two Years Ago After Trump Deal Raises NICE Spending Limit

NHS Approves Breast Cancer Drug Rejected Two Years Ago After Trump Deal Raises NICE Spending Limit

NICE has approved Enhertu for eligible women in England after a new drug deal and higher cost-effectiveness threshold made the treatment affordable for NHS funding.

International Business Times UK · Sep 17

Women in England with incurable breast cancer to get life-extending drug on NHS

Women in England with incurable breast cancer to get life-extending drug on NHS

Thousands with HER2-low advanced breast cancer will have access to Enhertu after ministers strike deal on price

The Guardian - UK · Sep 17

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Breast cancer drug blocked for NHS use as price talks break down for third time

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.

Evening Standard · Nov 19, 2024

Breast cancer drug blocked for NHS use as price talks break down – leaving charities ‘beyond devastated’

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu

The Independent UK · Nov 19, 2024

Women in England and Wales denied ‘exciting’ drug that can stop breast cancer spreading

Latest study shows Enhertu, rejected by Nice, can stall growth of tumours by a year, longer than standard chemotherapy

The Guardian - UK · Jun 3, 2024

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

Benzinga · Apr 27, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Coverage From

People

216,591 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Breast Cancer Now

AstraZeneca Plc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

150,457 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play